This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Baxter Reports Results Of ADVATE Real-World Experience From Worldwide Post-Marketing Database Of Hemophilia A Patients

Baxter International Inc. (NYSE:BAX) today presented two comprehensive analyses supporting the proven clinical and real-world results of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] during the 24 th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands. The presentations include two complementary studies of the ADVATE profile, including an analysis of post-marketing data from approximately 1,200 hemophilia A patients across 15 countries as well as safety findings from a 10-year database of 12 clinical trials.

A meta-analysis of post-authorization safety studies (PASS) (abstract# PO148) presented at ISTH supports the overall product safety and effectiveness profile, as well as low rate of inhibitor development with ADVATE, with only one de-novo inhibitor in severe previously-treated patients (n=669) with more than 150 prior exposure days. 1 The analysis assessed the effectiveness of ADVATE treatment in non-controlled, real-world clinical practice, and found that the median annual bleed rate (ABR) for patients on continuous prophylaxis (twice a week or more, n=560) was 1.67, which supports the ABR reported in controlled clinical studies. 2 The effectiveness result in the study captured ADVATE efficacy in routine clinical practice (as opposed to efficacy, which measures in a controlled, interventional trial setting). The meta-analysis included patients from the United States, Australia, Japan, and 12 countries in Europe, who were followed for more than one year with exposure to ADVATE ranging between 85 and 103 mean exposure days across five studies. 1

''This meta-analysis of the post-market surveillance database, the largest available in hemophilia today, demonstrates a global patient experience with ADVATE that is consistent with the results reported in our highly controlled clinical programs,'' said Bruce Ewenstein, M.D., Ph.D., vice president of clinical affairs for Baxter. ''Given the broad range of patients and hemophilia clinical practice around the world, it is significant that these data continue to support the low inhibitor rate among patients using ADVATE as well as the effectiveness of bleed prevention when on an ADVATE prophylaxis regimen.''

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.24 1.30%
FB $99.80 -4.10%
GOOG $683.10 -0.07%
TSLA $148.02 -9.00%
YHOO $27.05 -3.30%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs